NASDAQ:JBIO Jade Biosciences (JBIO) Stock Price, News & Analysis $19.92 +0.03 (+0.13%) As of 03:19 PM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsNews and TrendsOwnershipSEC FilingsShort Interest About Jade Biosciences Stock (NASDAQ:JBIO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Jade Biosciences alerts:Sign Up Key Stats Today's Range$19.00▼$20.1550-Day Range$19.15▼$24.7152-Week Range$6.91▼$28.00Volume456,196 shsAverage Volume715,727 shsMarket Capitalization$1.27 billionP/E RatioN/ADividend YieldN/APrice Target$51.75Consensus RatingModerate Buy Company Overview Jade Biosciences, Inc. is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics for inflammatory skin diseases and chronic itch. Leveraging a small‐molecule platform, the company seeks to address significant unmet needs in dermatology by targeting key pathways involved in pruritus and skin inflammation. Its research efforts are centered on identifying and advancing molecules that can modulate receptor activity in the skin, with a goal of improving safety and efficacy compared to existing treatments. The company’s lead programs are built around proprietary compounds designed to penetrate the epidermal barrier and selectively inhibit molecular drivers of itch and inflammation. Preclinical studies have demonstrated promising activity in models of atopic dermatitis, psoriasis‐associated itch and other dermatologic conditions, supporting the progression of these candidates into human trials. Jade Biosciences’ pipeline strategy includes both topical and systemic formulations to broaden the therapeutic scope across multiple indications. Founded in the mid‐2010s and incorporated in Delaware, Jade Biosciences maintains its headquarters in New Haven, Connecticut. The company’s management team draws on experience from established pharmaceutical and biotechnology organizations, combining expertise in medicinal chemistry, dermatology and clinical development. Listed on the Nasdaq under the ticker JBIO, Jade Biosciences is working to advance its pipeline through clinical milestones while preparing for potential partnerships and regulatory filings in the United States and other key markets. AI Generated. May Contain Errors. Read More Jade Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks41st Percentile Overall ScoreJBIO MarketRank™: Jade Biosciences scored higher than 41% of companies evaluated by MarketBeat, and ranked 636th out of 906 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingJade Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 2 strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialJade Biosciences has a consensus price target of $51.75, representing about 162.3% upside from its current price of $19.73.Amount of Analyst CoverageJade Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Jade Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Jade Biosciences are expected to decrease in the coming year, from ($2.84) to ($3.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Jade Biosciences is -10.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Jade Biosciences is -10.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioJade Biosciences has a P/B Ratio of 2.93. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.72% of the float of Jade Biosciences has been sold short.Short Interest Ratio / Days to CoverJade Biosciences has a short interest ratio ("days to cover") of 10.15, which indicates bearish sentiment.Change versus previous monthShort interest in Jade Biosciences has recently increased by 11.04%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldJade Biosciences does not currently pay a dividend.Dividend GrowthJade Biosciences does not have a long track record of dividend growth. News and Social Media2.3 / 5News SentimentN/A News SentimentJade Biosciences has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Jade Biosciences this week, compared to 3 articles on an average week.Search Interest2 people have searched for JBIO on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Jade Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders23.06% of the stock of Jade Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsJade Biosciences has minimal institutional ownership at this time.Read more about Jade Biosciences' insider trading history. Receive JBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Jade Biosciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. JBIO Stock News HeadlinesJade Biosciences to Participate in Upcoming ConferencesSeptember 1, 2026 | globenewswire.comJade Biosciences: Duration Is The Real ProductAugust 19, 2026 | seekingalpha.comThis looks like plywood. It's not.AI data centers have a power problem nobody likes to talk about. A single rack of computers can now use more electricity than an entire office building. One new chip, which looks more like a piece of plywood than a processor, delivers similar performance on a fraction of the power. Tech investing veteran George Gilder says that efficiency gap could decide who wins the next stage of AI. Gilder has identified three companies positioned around this power breakthrough, calling them the Trillion Dollar Triangle.September 8 at 1:00 AM | Eagle Publishing (Ad)Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate UpdateAugust 10, 2026 | markets.businessinsider.comJade Biosciences Inc JBIOAugust 2, 2026 | morningstar.comMJade Biosciences Stock Short Interest Report | NASDAQ:JBIO | BenzingaJuly 20, 2026 | benzinga.comIs Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market?June 30, 2026 | finance.yahoo.comJade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of DirectorsJune 26, 2026 | globenewswire.comSee More Headlines JBIO Stock Analysis - Frequently Asked Questions How have JBIO shares performed this year? Jade Biosciences' stock was trading at $15.43 at the beginning of the year. Since then, JBIO shares have increased by 27.9% and is now trading at $19.7310. How were Jade Biosciences' earnings last quarter? Jade Biosciences, Inc. (NASDAQ:JBIO) released its quarterly earnings results on Monday, August, 10th. The company reported ($0.76) EPS for the quarter, missing analysts' consensus estimates of ($0.66) by $0.10. Who are Jade Biosciences' major shareholders? Top institutional shareholders of Jade Biosciences include California State Teachers Retirement System (1.58%), Wellington Management Group LLP (0.14%), Bank of New York Mellon Corp (0.17%) and Corient Private Wealth LP (0.10%). How do I buy shares of Jade Biosciences? Shares of JBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/10/2026Today9/08/2026Wells Fargo 21st Annual Healthcare Conference9/08/2026Citi 2026 Biopharma Back to School Summit9/09/2026H.C. Wainwright 28th Annual Global Investment Conference9/15/2026Stifel 2026 Virtual Immunology and Inflammation Forum9/23/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 JBIO's financial health is in the Green zone, according to TradeSmith. JBIO has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:JBIO Previous SymbolNASDAQ:JBIO CIK1798749 Webaerovatetx.com Phone(617) 443-2400FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Price Target for Jade Biosciences$51.75 High Price Target$77.00 Low Price Target$40.00 Potential Upside/Downside+159.7%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)($1.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$127.41 million Net MarginsN/A Pretax MarginN/A Return on Equity-49.11% Return on Assets-45.62% Debt Debt-to-Equity RatioN/A Current Ratio14.93 Quick Ratio14.93 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.74 per share Price / Book2.96Miscellaneous Outstanding Shares63,600,000Free Float48,932,000Market Cap$1.27 billion OptionableN/A Beta1.45 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:JBIO) was last updated on 9/8/2026 by MarketBeat.com Staff. From Our PartnersTrump Is Finally Fighting For Your Retirement. Buffett's Still Not Convinced?Warren Buffett has built one of the largest cash positions in Berkshire Hathaway's history even as markets hit...Preserve Gold | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredGold Explorer Sits Between Barrick’s Nevada GiantsBarrick Mining has spent decades building one of Nevada's richest gold districts, anchored by Fourmile, Goldru...Wall Street Logic | SponsoredWhy the Treasury still prices gold at 42 dollars an ounceThe U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades n...Golden Portfolio | SponsoredEarth's biggest energy source: near Grand CanyonThe largest energy source on Earth contains 50,000 times every oil and gas reserve on the planet combined - an...Behind the Markets | SponsoredModerna’s 177% Surge Puts Cancer Biotech Back in FocusModerna shares surged 177% in a single trading session on August 19, adding about $45 billion in market value ...The Tomorrow Investor | SponsoredThe 2026 beginners Guide to Gold IRAsGold trades near record highs while silver just topped $81 an ounce for the first time ever. Thousands of A...Goldco Direct, LLC | SponsoredAmerican retirees will miss THIS. Big Banks just moved in.Central banks spent nearly $130 billion on physical gold last year, on top of $145 billion the year before. Q1...Cedar Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Jade Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Jade Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
